Singapore's national platform for drug discovery and development, has announced the presentation of updated clinical data for ...

The expansion cohort for pancreatic ductal adenocarcinoma (PDAC) in the ongoing Phase 1 trial has completed enrolment. Notably, 82% of patients had tumours expressing the antigen at levels considered ...

The first-in-class antibody-drug conjugate (ADC) pivekimab sunirine (PVEK) demonstrated promising efficacy and high response ...

The first-in-class antibody-drug conjugate (ADC) pivekimab sunirine (PVEK) demonstrated promising efficacy and high response ...

Toxicities related to Teliso-V are manageable for patients with c-Met overexpressing non-small cell lung cancer, according to ...

Avenzo Therapeutics Initiates Phase 1/2 Clinical Study of AVZO-1418, a Potential Best-in-Class, Novel EGFR/HER3 Bispecific Antibody-Drug Conjugate ...

Takeda (NYSE:TAK) (4502.T) said on Monday that the European Commission approved Pfizer (NYSE:PFE) and the company's antibody-drug conjugate, Adcetrix, in combination with a chemotherapy regimen in ...

A new targeted cancer drug, DB-1310, is showing early signs of effectiveness in patients with advanced solid tumors that have ...

Simris Group AB (publ), through its wholly owned subsidiary Simris Biologics GmbH, has signed a non-binding concept sheet with a EU based biopharmaceutical company specializing in the development of ...

CHICAGO -- Combining pembrolizumab (Keytruda) with sacituzumab govitecan (SG, Trodelvy) instead of chemotherapy as first-line ...

Gilead has already announced intentions to bring the data, which demonstrated a 35 percent reduction in risk of progression ...

AstraZeneca and Daiichi Sankyo’s drug extended survival by 30% compared to a widely used regimen, further establishing its ...